Jpmorgan Chase & CO Kazia Therapeutics LTD Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 37,826 shares of KZIA stock, worth $240,573. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,826
Previous 3
1260766.67%
Holding current value
$240,573
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding KZIA
# of Institutions
16Shares Held
1.73MCall Options Held
24KPut Options Held
0-
Mai Capital Management1.36MShares$8.67 Million0.01% of portfolio
-
Morgan Stanley New York, NY201KShares$1.28 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$263,8000.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$249,8010.0% of portfolio
-
Commonwealth Equity Services, LLC30.5KShares$193,9800.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $96.1M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...